For localized information and support, would you like to switch to your country-specific website for {0}?
Contact us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
- Insights
- Diagnostics insights
- Roche and PathAI: Defining the next era of digital pathology
Key takeaways
- Roche and PathAI combine expertise in tissue diagnostics, digital pathology solutions, and AI to support clinical laboratories and biopharma research
- Our open, end-to-end digital pathology ecosystem streamlines contracting, implementation, service, and technical support
- AISight®, a cloud-native platform can simplify laboratory workflows, accelerate biomarker discovery, and deliver insights that support more personalized patient care
Combining state-of-the-art, AI-powered digital pathology technologies with leading diagnostic platforms to transform precision oncology
To lead the next era of computational pathology, Roche is investing in providing more seamless access to digital pathology for labs, researchers, and patients. Roche has united its global footprint and market leadership in tissue diagnostics with PathAI, a leader in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry, to redefine how diagnostics generate value for patients across the globe.
About PathAI
PathAI is a leader in AI-powered pathology with a mission to improve patient outcomes. By combining deep pathology expertise with advanced artificial intelligence, PathAI develops technology solutions aiming to provide invaluable insights for biomarker discovery and drug development, and to improve laboratory workflows.
PathAI built a vertically integrated technology stack trained on a massive, highly curated proprietary dataset including:
- 42.5+ million annotations
- A network of 500+ pathologists providing expert oversight
- A proprietary dataset of over ~800,000 whole slide images
- A state-of-the-art universal transformer foundation model PLUTO pre-trained on ~2,000,000 image tiles for rapid adaptation to diverse diagnostic and research tasks1
This pathologist-trained foundation includes a large menu of AI algorithms, bringing unprecedented precision to the future of clinical diagnostics and biopharma research.
Our vision for an end-to-end digital pathology solution
In a modern digital workflow, clinical and research laboratories face a hidden barrier to scaling: The complexity of managing multiple vendors, disjointed contracts, and fragmented service teams. To truly operationalize digital pathology, labs need a partner that simplifies how they do business.
Roche is driving a standard for the market: True open and end-to-end digital pathology. Instead of navigating multiple points of contact for contracting and service, Roche aims to streamline operations by offering:
One partner
A single partner for the entire digital pathology ecosystem including PathAI’s agile and innovative AI tools.
One setup
A unified, streamlined setup process with minimal operational downtime.
One support team
A single, dedicated contact for service and technical support.
One contract
Simple contracting and unified billing options.
Many laboratories currently believe that "end-to-end" means being locked into a closed ecosystem. Roche believes an end-to-end workflow should be designed to implement seamlessly and support digital pathology across the lab, even with scanners or AI algorithms from other developers.
A unified ecosystem for the modern lab
Today, this union delivers a seamless, cloud-native platform that bridges clinical labs and pharma discovery. Our unified vision is built on complete compatibility and interoperability. At the center of this is AISight®—a robust, open image management system (IMS). Our secure platform focuses on enabling:
- Increased efficiencies: Streamlining workflows through automation to deliver fast and consistent results for patients.
- Accelerated discovery and development: Using advanced AI to find new biomarkers and develop novel diagnostic tools for biopharma.
- Empowered physicians: Providing deeper insights to help clinicians tailor cancer treatments to the individual patient.
A shared future for Roche and PathAI
By bringing together Roche’s global presence in anatomic pathology with PathAI’s innovative digital pathology platforms and AI tools, Roche is leading the way into the next era of digital pathology.
Improve patient outcomes with AI-powered pathology
PathAI transforms healthcare through AI-powered pathology. Their AISight platform empowers biopharma and clinical labs to accelerate drug development, discover biomarkers, and help improve patient outcomes with precision medicine.
Contributors
Roche Diagnostics
Roche Diagnostics is a division of Roche, developing and integrating diagnostic solutions that address today’s healthcare challenges while anticipating tomorrow’s needs. In more than 100 countries, we provide one of the industry’s most comprehensive in vitro diagnostics portfolios spanning molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, Point of Care testing, patient self-testing, next-generation sequencing, laboratory automation and IT, as well as digital health and decision-support solutions.
Our articles are authored by Roche Diagnostics subject matter experts, drawing on collective expertise across multiple disciplines to provide reliable insights for healthcare professionals worldwide.
Explore articles from our community
?wid=384&hei=216&fmt=png-alpha&fit=crop,1&cropn=0.07,0,0.86,1)
?wid=384&hei=216&fmt=png-alpha&fit=crop,1&cropn=0.07,0,0.86,1)
?wid=384&hei=216&fmt=png-alpha&fit=crop,1&cropn=0.07,0,0.86,1)
No insights found
Contact us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
AISight® is for Research Use Only. Not for use in diagnostic procedures.
AISight® Dx is FDA-cleared for primary diagnosis in the US.
AISight® Dx is CE-IVD-marked for primary diagnosis in the EEA, CH, and UK.
References
- Padigela H, et al. PLUTO-4: Frontier Pathology Foundation Models. ArXiv. 2025;3:abs/2511.02826.